pSivida Corp - Sustained Release Biologics: The Missing Piece

Accesswire

pSivida Corp (PSDV) today published a new blog post on The Chairman’s Blog, written by the company’s President and CEO, Dr. Paul Ashton. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Dr. Ashton provides insights into the successes and failures of the biotech revolution and how the difficulties of delivering biologics leads to opportunities for drug delivery. The missing piece to biologics, according to Dr. Ashton, is technology, which he believes can help a company do well moving forward in the biotech world: “Companies who can provide the ‘Technology’ (i.e. an ability to deliver biologics) that leads to Transformational Change are likely to do extremely well.” Read the full blog post from Dr. Paul Ashton on TheChairmansBlog.com (http://www.thechairmansblog.com/paul-ashton/2013-08/sustained-release-biologics-the-missing-piece.html).

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorization in Italy. Alimera has resubmitted the New Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration. pSivida plans to institute pivotal Phase III clinical trials for the treatment of posterior uveitis, a chronic back-of-the-eye disease, with the same micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida's FDA-approved Retisert® licensed to Bausch & Lomb Incorporated provides long-term, sustained drug delivery to treat posterior uveitis. http://www.psivida.com/

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information. http://www.thechairmansblog.com/

Source: pSivida Corp.

View Comments (0)